ArticleCancer gene therapy2026
Dioscin suppresses tumorigenesis and overcomes radioresistance by promoting ubiquitination-mediated degradation of Mcl-1.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is a prevalent and aggressive malignancy of the oral cavity, with increasing incidence and poor prognosis. Myeloid leukemia 1 (Mcl-1), an anti-apoptotic protein in the BCL-2 family, is critical for tumor development and progression. In this study, we investigated Dioscin, a natural compound, as a potential therapeutic agent for OSCC. Our results demonstrated that Dioscin significantly inhibits cell viability and colony formation in OSCC cell lines. Mechanistically, Dioscin induced intrinsic apoptosis by promoting the ubiquitination and degradation of Mcl-1. Further analysis revealed that Dioscin enhances the interaction between the E3 ligase β-TRCP and Mcl-1 by inhibiting the Akt/GSK3β signaling pathway, resulting in increased phosphorylation of Mcl-1 at Ser159, which drives its destabilization. In vivo, Dioscin notably suppressed OSCC tumor growth, including in sensitive and radioresistant cells, by reducing Mcl-1 levels. These findings highlight the therapeutic potential of Dioscin for OSCC treatment, offering new insights for overcoming radioresistance and improving clinical outcomes in OSCC patients.
Indexed as
Identifiers
41876846What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.